Pill camera is an application of nanotechnology used in medicine to diagnose the disease particularly the small intestine and it is an alternative to endoscopy.
Dr. Shikhman discusses reasons why you still may not feel well even after going gluten free. Covering leaky gut syndrome, yeast overgrowth, food allergies, endocrine abnormalities.
On March 14 I presented the history of my research activities and proposals for MS Biology thesis work for the students entering the program at National University,
Pill camera is an application of nanotechnology used in medicine to diagnose the disease particularly the small intestine and it is an alternative to endoscopy.
Dr. Shikhman discusses reasons why you still may not feel well even after going gluten free. Covering leaky gut syndrome, yeast overgrowth, food allergies, endocrine abnormalities.
On March 14 I presented the history of my research activities and proposals for MS Biology thesis work for the students entering the program at National University,
La terapia medica e chirurgica della malattia perianale di Crohn - Gastrolear...Gastrolearning
Gastrolearning II modulo/21a lezione
La terapia medica e chirurgica della malattia perianale di Crohn
Relatore: Prof. Paolo Gionchetti (Università di Bologna)
Epatocarcinoma: nulla di nuovo sotto il sole - Gastrolearning®Gastrolearning
Gastrolearning II modulo/13a lezione
Epatocarcinoma: nulla di nuovo sotto il sole
Relatore: Prof. Massimo Colombo (Milano)
Discussants: Prof. F. Farinati (Padova), Prof.ssa E. Villa (Modena), Prof. A. Grieco (Roma).
Il trattamento chirurgico del colangiocarcinoma - Gastrolearning®Gastrolearning
Gastrolearning II modulo/8a lezione
Il trattamento chirurgico del colangiocarcinoma
Prof. Gian Luca Grazi - Hepato-Biliary-Pancreatic Surgery National Cancer Institute Regina Elena, Roma
Il colangiocarcinoma: Presentazione Clinica, Diagnosi e Trattamento - Gastrol...Gastrolearning
Gastrolearning II modulo/8a lezione
Il colangiocarcinoma: Presentazione Clinica, Diagnosi e Trattamento
Prof. D. Alvaro - Università di Roma La Sapienza
Il colangiocarcinoma: Epidemiologia, Fattori di rischio e patogenesi - Gastro...Gastrolearning
Gastrolearning II modulo/7a lezione
Il colangiocarcinoma: Epidemiologia, Fattori di rischio e patogenesi
Prof. D. Alvaro - Università di Roma La Sapienza
La terapia medica e chirurgica della malattia perianale di Crohn - Gastrolear...Gastrolearning
Gastrolearning II modulo/21a lezione
La terapia medica e chirurgica della malattia perianale di Crohn
Relatore: Prof. Paolo Gionchetti (Università di Bologna)
Epatocarcinoma: nulla di nuovo sotto il sole - Gastrolearning®Gastrolearning
Gastrolearning II modulo/13a lezione
Epatocarcinoma: nulla di nuovo sotto il sole
Relatore: Prof. Massimo Colombo (Milano)
Discussants: Prof. F. Farinati (Padova), Prof.ssa E. Villa (Modena), Prof. A. Grieco (Roma).
Il trattamento chirurgico del colangiocarcinoma - Gastrolearning®Gastrolearning
Gastrolearning II modulo/8a lezione
Il trattamento chirurgico del colangiocarcinoma
Prof. Gian Luca Grazi - Hepato-Biliary-Pancreatic Surgery National Cancer Institute Regina Elena, Roma
Il colangiocarcinoma: Presentazione Clinica, Diagnosi e Trattamento - Gastrol...Gastrolearning
Gastrolearning II modulo/8a lezione
Il colangiocarcinoma: Presentazione Clinica, Diagnosi e Trattamento
Prof. D. Alvaro - Università di Roma La Sapienza
Il colangiocarcinoma: Epidemiologia, Fattori di rischio e patogenesi - Gastro...Gastrolearning
Gastrolearning II modulo/7a lezione
Il colangiocarcinoma: Epidemiologia, Fattori di rischio e patogenesi
Prof. D. Alvaro - Università di Roma La Sapienza
A review of the growth of the Israel Genealogy Research Association Database Collection for the last 12 months. Our collection is now passed the 3 million mark and still growing. See which archives have contributed the most. See the different types of records we have, and which years have had records added. You can also see what we have for the future.
Biological screening of herbal drugs: Introduction and Need for
Phyto-Pharmacological Screening, New Strategies for evaluating
Natural Products, In vitro evaluation techniques for Antioxidants, Antimicrobial and Anticancer drugs. In vivo evaluation techniques
for Anti-inflammatory, Antiulcer, Anticancer, Wound healing, Antidiabetic, Hepatoprotective, Cardio protective, Diuretics and
Antifertility, Toxicity studies as per OECD guidelines
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...Levi Shapiro
Letter from the Congress of the United States regarding Anti-Semitism sent June 3rd to MIT President Sally Kornbluth, MIT Corp Chair, Mark Gorenberg
Dear Dr. Kornbluth and Mr. Gorenberg,
The US House of Representatives is deeply concerned by ongoing and pervasive acts of antisemitic
harassment and intimidation at the Massachusetts Institute of Technology (MIT). Failing to act decisively to ensure a safe learning environment for all students would be a grave dereliction of your responsibilities as President of MIT and Chair of the MIT Corporation.
This Congress will not stand idly by and allow an environment hostile to Jewish students to persist. The House believes that your institution is in violation of Title VI of the Civil Rights Act, and the inability or
unwillingness to rectify this violation through action requires accountability.
Postsecondary education is a unique opportunity for students to learn and have their ideas and beliefs challenged. However, universities receiving hundreds of millions of federal funds annually have denied
students that opportunity and have been hijacked to become venues for the promotion of terrorism, antisemitic harassment and intimidation, unlawful encampments, and in some cases, assaults and riots.
The House of Representatives will not countenance the use of federal funds to indoctrinate students into hateful, antisemitic, anti-American supporters of terrorism. Investigations into campus antisemitism by the Committee on Education and the Workforce and the Committee on Ways and Means have been expanded into a Congress-wide probe across all relevant jurisdictions to address this national crisis. The undersigned Committees will conduct oversight into the use of federal funds at MIT and its learning environment under authorities granted to each Committee.
• The Committee on Education and the Workforce has been investigating your institution since December 7, 2023. The Committee has broad jurisdiction over postsecondary education, including its compliance with Title VI of the Civil Rights Act, campus safety concerns over disruptions to the learning environment, and the awarding of federal student aid under the Higher Education Act.
• The Committee on Oversight and Accountability is investigating the sources of funding and other support flowing to groups espousing pro-Hamas propaganda and engaged in antisemitic harassment and intimidation of students. The Committee on Oversight and Accountability is the principal oversight committee of the US House of Representatives and has broad authority to investigate “any matter” at “any time” under House Rule X.
• The Committee on Ways and Means has been investigating several universities since November 15, 2023, when the Committee held a hearing entitled From Ivory Towers to Dark Corners: Investigating the Nexus Between Antisemitism, Tax-Exempt Universities, and Terror Financing. The Committee followed the hearing with letters to those institutions on January 10, 202
Executive Directors Chat Leveraging AI for Diversity, Equity, and InclusionTechSoup
Let’s explore the intersection of technology and equity in the final session of our DEI series. Discover how AI tools, like ChatGPT, can be used to support and enhance your nonprofit's DEI initiatives. Participants will gain insights into practical AI applications and get tips for leveraging technology to advance their DEI goals.
Introduction to AI for Nonprofits with Tapp NetworkTechSoup
Dive into the world of AI! Experts Jon Hill and Tareq Monaur will guide you through AI's role in enhancing nonprofit websites and basic marketing strategies, making it easy to understand and apply.
বাংলাদেশের অর্থনৈতিক সমীক্ষা ২০২৪ [Bangladesh Economic Review 2024 Bangla.pdf] কম্পিউটার , ট্যাব ও স্মার্ট ফোন ভার্সন সহ সম্পূর্ণ বাংলা ই-বুক বা pdf বই " সুচিপত্র ...বুকমার্ক মেনু 🔖 ও হাইপার লিংক মেনু 📝👆 যুক্ত ..
আমাদের সবার জন্য খুব খুব গুরুত্বপূর্ণ একটি বই ..বিসিএস, ব্যাংক, ইউনিভার্সিটি ভর্তি ও যে কোন প্রতিযোগিতা মূলক পরীক্ষার জন্য এর খুব ইম্পরট্যান্ট একটি বিষয় ...তাছাড়া বাংলাদেশের সাম্প্রতিক যে কোন ডাটা বা তথ্য এই বইতে পাবেন ...
তাই একজন নাগরিক হিসাবে এই তথ্য গুলো আপনার জানা প্রয়োজন ...।
বিসিএস ও ব্যাংক এর লিখিত পরীক্ষা ...+এছাড়া মাধ্যমিক ও উচ্চমাধ্যমিকের স্টুডেন্টদের জন্য অনেক কাজে আসবে ...
How to Build a Module in Odoo 17 Using the Scaffold MethodCeline George
Odoo provides an option for creating a module by using a single line command. By using this command the user can make a whole structure of a module. It is very easy for a beginner to make a module. There is no need to make each file manually. This slide will show how to create a module using the scaffold method.
Advantages and Disadvantages of CMS from an SEO Perspective
Non-celiac glutensensitivity - Gastrolearning®
1. NON COELIAC GLUTEN
SENSITIVITY (NCGS)
GR Corazza
I Clinica Medica
Fondazione IRCCS Policlinico San Matteo
Università di Pavia
2. THE DEFINITION OF COELIAC DISEASE
CD is a chronic inflammatory disease
characterised by flattened villi on the small
bowel mucosa and is induced in genetically
susceptible people by the ingestion of
proline-rich and glutamine-rich proteins
contained in wheat, rye and barley (gluten)
Lancet 2009
3. EVOLUTION OF MUCOSAL
PATTERN IN COELIAC DISEASE
glu
mosaic t en
-fr
ee
die
t
convolutions
ridges & leaves
finger villi
4. THE RELEVANCE OF COELIAC DISEASE
CLINICAL POINTS RESEARCH AGENDA
• ↑↑↑ prevalence (1:100-1:150) • monoetiology
• ↑↑↑ clinical heterogeneity • HLA-linked
• ↑↑ co-morbidity • predisposing to lymphoma
• ↑ mortality (2:1) • reinduction of tolerance
6. THE CLINICAL GALAXY OF CD
POTENTIAL CD LATENT CD
pts with normal mucosa who
pts with positive serology but
subsequently develop villus
with (still) normal mucosa
atrophy (retrospective
recogniction)
SILENT CD MAJOR CD MINOR CD
pts complaining of trivial,
pts who do not complain
pts complaining of frank transient or apparently
of any symptom and
malabsorbtion symtomps and unrelated symtomps,
biopsied because of
biopsied because of them biopsied because of
active case finding
positive serology
? GLUTEN
REFRACTORY CD SENSITIVITY ?
RCD type I pts complaining of various
RCD type II symptoms, with normal
Ulcerative enteritis mucosa, negative serology
ETCL and not HLA-linked
7. MISDIAGNOSIS AND DIAGNOSTIC DELAY IN CD
Pts previously Pts with no previous
misdiagnosed misdiagnosis
(n=196) (n=223) p
12.9 ± 12.9 8.0 ± 12.5 < 0.005
Pts with major Pts with minor
presentation presentation
(n=129) (n=67) p
14.0 ± 13.8 9.7 ± 9.2 < 0.05
J Clin Gastroenterol 1996
8. IS COELIAC DISEASE MIS/OVERDIAGNOSED?
RESULTS OF 605 CONSECUTIVE CASES REFERRED
TO UNIVERSITY OF PAVIA (1999/2005)
False Predictors
605
Clinical diagnosis
187-24 Unconventional tests
questioned
Poor sample quality
52+27 Marsh 1/2 lesions
refused tTG false-positivity
In press
9. PATHOLOGIST AGREEMENT
WITHIN MARSH CLASSIFICATION
Categories K Values
M–H type 0 0.46 0.58
M–H type 1 0.23 0.03
M–H type 2 0.04 0.01
M–H type 3a 0.19 0.30
M–H type 3b 0.24 0.18
M–H type 3c 0.64 0.50
Corazza et al, Clin Gastroenterol Hepatol 2007
Arguelles-Grande et al, J Clin Pathol 2012
10. THE CLINICAL GALAXY OF CD
POTENTIAL CD LATENT CD
pts with normal mucosa who
pts with positive serology but
subsequently develop villus
with (still) normal mucosa
atrophy (retrospective
recogniction)
SILENT CD MAJOR CD MINOR CD
pts complaining of trivial,
pts who do not complain
pts complaining of frank transient or apparently
of any symptom and
malabsorbtion symtomps and unrelated symtomps,
biopsied because of
biopsied because of them biopsied because of
active case finding
positive serology
? GLUTEN
REFRACTORY CD SENSITIVITY ?
RCD type I pts complaining of various
RCD type II symptoms, with normal
Ulcerative enteritis mucosa, negative serology
ETCL and not HLA-linked
11. NCGS - DEFINITION
• symptoms -ranging from abdominal pain to foggy mind-
that improve or disappear after gluten withdrawal
• lack of intestinal lesion
• negativity of anti-transglutaminase and anti-endomysial
antibodies
• unrelated to a specific HLA status
• very high prevalence (6 times >> CD !)
• standardized mortality ratio= 2.4 ? (IgG AGA+/IgA EMA-)
12. NCGS - FIRST CASE HISTORIES
a F 43yr old presented after 2 yrs of diarrhoea, periumbilical pain,
abdominal distension. No improvement with tetracycline or antidiarrhoeals.
Intestinal biopsy and other tests: –ve. All symptoms stopped within 4d of
GFD and worsened after 6wks of gluten challenge.
Ellis & Linaker, Lancet 1978
a F 16mo old referred for diarrhoea, irritability and loss of appetite.
Intestinal biopsy and other tests: –ve. Because of family history a GFD was
started and within a few days symptoms subsided. Rechallenge →
diarrhoea within 24h.
Jonas, Lancet 1978
a F 24yr old presented with 1mo history of vomiting, abdominal pain, loss
of 7kg in weight and 8-10 loose stools/d. Intestinal biopsy → only slight
villous oedema. Prick tests: +ve for gluten and wheat flour. All symptoms
disappeared on a GFD.
Dahl, Lancet 1978
13. NCGS - ITS COMPELLING REVIVAL
Celebrity Endorsement: Gwyneth
Paltrow, Victoria Beckham and
Oprah Winfrey swear by gluten
exclusion from the diet for its
health benefit and detox effect
Everydayhealth.com 2011
L’Espresso 2012
14. NCGS - POPULAR PRESS RISE THE CLAIM
… gluten: the new diet villain …
Newsweek 2008
… 17 million Americans are estimated to
be gluten-sensitive …
Washington Post 2011
… 15 to 25% of the general American
population want gluten-free foods …
USA Today 2008
15. NCGS - GOOGLE / PUBMED CITATIONS
NCGS: SENSE OR SENSIBILITY ?
4000
3000
ratios
2000
1000
0
Gluten Breast Colon GERD Alzheimer’s Coeliac Lung Parkinson’s
Sensitivity Cancer Cancer Disease Disease Cancer Disease
Ann Intern Med 2012
16. CLINICAL POINTS IN COELIAC DISEASE (CD)
AND NON-COELIAC GLUTEN SENSITIVITY (NCGS)
NON-COELIAC
COELIAC DISEASE GLUTEN-SENSITIVITY
• prevalence (1:100-1:150) • supposed to be higher than CD
• ↑↑↑ clinical heterogeneity • ↑↑↑ clinical heterogeneity
• ↑↑ co-morbidity • ? co-morbidity
• ↑ mortality (2:1) • ? mortality
17. AN IDENTIKIT OF PATIENTS WITH NCGS
• many of these patients were formerly on highly restrictive diets
• many of these patients withdrawn gluten from their diet
• many of these patients were convinced that exclusion of the gluten
from the diet had helped their IBS-like symptoms
18. EPIDEMIOLOGY OF GLUTEN SPECTRUM
DISORDERS IN USA
Gluten spectrum disorders
Wheat allergy Non-coeliac GS Coeliac disease Occasional consumers
∼300,000 people ∼20,000,000 people ∼2,700,000 people ∼37,000,000
(0.1% gen popul) (6% gen popul) (1% gen popul) (15% gen popul)
Fasano A. FISMAD, March 29th, Naples 2012
19. NCGS. THE SIZE OF THE PROBLEM
5,896 patients referring to the Gastro Unit
GS-symptoms
80
347 NCGS pts (6%) EMA/TTG negative
70
Not allergic
60
68
Patients (%)
50
40
30 35 34 33 33
20
22 20
10
0
Abdominal Headache Foggy Chronic Diarrhoea Depression Anaemia
pain mind fatigue
Sapone A. Symposium on Gluten sensitivity, February 9th, Bologna 2012
20. PEOPLE FREQUENTLY MISATTRIBUTE
ABDOMINAL SYMPTOMS TO FOOD INTOLERANCE
• although many patients are certain that they can link the ingestion of
various foods to subsequent abdominal symptoms, it is extremely difficult
to pinpoint accurately which, if any, constituents of the diet cause
abdominal distress
• there is a tendency to attribute symptoms to a food that others have
declared to be a problem -for example lactose or gluten-, and this
conclusion is reinforced by an apparent improvement in symptoms when
the food is avoided
• given the enormous placebo effect of food, to document a food intolerance
reliably it must be demonstrated that ingestion of the putative offender
results in symptoms that do not occur when a placebo, that appears and
tastes identical, is ingested
Levitt, NEJM 1995
21. NCGS - THE BIRMINGHAM STUDY
Symptoms after gluten 30 g F.U. GFD
F.U. F.U. GFD at before
Patient Normal gluten Abd. Abd. double-blind
No diet (yr) challenge (mo) pain distension Diarrhea Malaise (mo)
1 7 9 + + - + 50
2 0.5 5 + + + + 46
3 1 24 + + + + 60
4 4.25 No challenge 44
5 0.5 12 + + - + 50
6 2 4 + + + + 42
7 4.25 7 + + - + 42
8 3.25 9 + + + + 40
9 0.75 5 + + + + 38
Cooper et al, Gastroenterology 1980
22. GLUTEN CAUSES GI SYMPTOMS IN SUBJECTS
WITHOUT CD: A DOUBLE-BLIND RANDOMIZED
PLACEBO-CONTROLLED TRIAL IN IBS PTS
Overall symptoms
Screened Gluten
(n=103) Placebo
No exclusion of CD
No consent to partecipate
Pain Bloating
Symptomatic on GFD
Randomised Satisfaction with
Tiredness
stool consistency
(n=39)
(1) (4)
Gluten Placebo Wind Nausea
(n=19) (n=15)
Biesiekierski et al. Am J Gastroenterol 2011
23. RETROSPECTIVE EVALUATION OF 43 CASES
WITH SUSPECTED NCGS
812 patients referring to the Gastro Unit in the last 10 months
GS-symptoms
80
43 NCGS pts (5.3%) EMA/TTG negative
70 74
Not allergic
60
Patients (%)
50
48
40
30
32
30
20 27
10
18
0
Abdominal Bloating Diarrhoea Headache Chronic Anaemia
pain fatigue
Di Sabatino et al. FISMAD, March 28-31, Naples 2012
25. NCGS - PUTATIVE MECHANISMS
Sapone et al, Int Arch Allergy Immunol 2010
Sapone et al, BMC Medicine 2011
26. BREATH HYDROGEN CONCENTRATION DURING A 10-HOUR FAST AND
AFTER INGESTION OF 100 G OF CARBOHYDRATES IN HEALTHY SUBJECTS
Fasting
Sucrose
Hydrogen concentration (ppm)
White wheat
bread
Pasta
Low-gluten
wheat bread
Low-gluten
wheat bread
+ Gluten
Rice bread
Hours Anderson et al. NEJM 1981
27. NCGS - POSSIBLE HETEROGENEITY
OF THE ETIOLOGICAL SPECTRUM
of gluten
Opioid-like activity
St rbo bso
as al
ca ala
ar h rp
se i n
es
m
ch yd tio
di test
ce ain
ra n
du xtr
IgE
d
te
ed
-in E
wh -med uc n
eat iat nd
/ye ed te n-i matio
ast
Glu nflam
en
al l e
ei
ut
r gy ad
gl
- gr
low
Innate immune
Placebo/nocebo effect of
reaction to gluten
gluten withdrawal/challenge
Ann Intern Med 2012
28. NCGS – PROVISIONAL CONCLUSIONS
• there is an absolute need of in-depth clinical research to
prevent the convinction that gluten is a toxin for most of
the population and that a possible health problem would
translate into a social-health problem
• self prescription of gluten withdrawal would lead to the
consequent preclusion of a correct diagnosis of CD and
to a high and unjustified economic burden
• at present a reliable marker of gluten sensitivity is not
readily available and double-blind placebo-controlled food
challenge tests are mandatory to confirm this diagnosis
Ann Intern Med 2012
29. NCGS – CHARACTERISTICS
AND INDICATIONS OF ORAL GLUTEN
CHALLENGE TESTS
Challenge Test Characteristics Indications
Ann Intern Med 2012